| Filing Date | Insider | Type | 10b5-1 | Net Shares | Ownership change | Avg. Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| 2025-12-23 | MARSHALL ALLAN Chief Executive Officer | Purchase | +50,000 | +1.25%4,046,261 | $1.80 | $90,000 | View SEC filing | |
| 2025-12-17 | MARSHALL ALLAN Chief Executive Officer | Purchase | +150,000 | +3.90%3,996,261 | $2.07 | $310,500 | View SEC filing | |
| 2025-11-21 | Salkind Gene Director | Purchase | +50,000 | +29.63%218,750 | $2.55 | $127,500 | View SEC filing | |
| 2025-11-18 | Salkind Gene Director | Purchase | +200,000 | +37.16%738,220 | $2.73 | $546,000 | View SEC filing | |
| 2025-07-30 | Salkind Gene Director, 10% Owner | Purchase | +20,243 | +5.54%385,370 | $4.94 | $100,000 | View SEC filing | |
| 2025-07-24 | Dugan Lawrence Director | Purchase | +16,000 | +29820.05%116,389 | $6.11 | $97,770 | View SEC filing | |
| 2025-07-24 | MARSHALL ALLAN Chief Executive Officer | Purchase | +161,943 | +18.31%1,046,261 | $4.94 | $799,998 | View SEC filing | |
| 2025-04-25 | MARSHALL ALLAN Chief Executive Officer | Purchase | +782,895 | +517.03%934,318 | $2.33 | $1,825,001 | View SEC filing | |
| 2025-04-25 | Norstrud Andrew James Chief Financial Officer | Purchase | +43,860 | +287.08%59,138 | $2.28 | $100,001 | View SEC filing | |
| 2025-04-25 | Salkind Gene Director, 10% Owner | Purchase | +241,229 | +194.70%365,127 | $2.28 | $550,002 | View SEC filing | |
| 2024-03-18 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +77,773 | +2.72%2,939,654 | $0.58 | $44,739 | View SEC filing | |
| 2024-03-06 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +103,013 | +3.73%2,861,881 | $0.70 | $72,109 | View SEC filing | |
| 2023-12-20 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +12,916 | +0.00%2,758,868 | $0.96 | $12,340 | View SEC filing | |
| 2023-12-07 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +90,001 | +3.38%2,754,333 | $0.94 | $84,952 | View SEC filing | |
| 2023-12-06 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +53,474 | +2.05%2,664,332 | $0.76 | $40,652 | View SEC filing | |
| 2023-11-29 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +375,000 | +18.00%2,458,333 | N/A | N/A | View SEC filing | |
| 2023-07-07 | MARSHALL ALLAN Chief Executive Officer | Purchase | +79,945 | +3.06%2,690,803 | $2.36 | $188,783 | View SEC filing | |
| 2023-05-23 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +22,776 | +0.88%2,610,858 | $3.41 | $77,739 | View SEC filing | |
| 2023-03-20 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +13,001 | +0.50%2,588,082 | $4.41 | $57,308 | View SEC filing | |
| 2023-01-11 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +17,303 | +0.68%2,575,081 | $3.69 | $63,909 | View SEC filing | |
| 2022-12-13 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +12,000 | +0.47%2,557,778 | $4.11 | $49,320 | View SEC filing | |
| 2022-12-05 | MARSHALL ALLAN CHIEF EXECUTIVE OFFICER | Purchase | +18,475 | +0.73%2,545,778 | $3.96 | $73,161 | View SEC filing | |
| 2022-04-01 | Salkind Gene Director, 10% Owner | Purchase | +125,000 | +100.00%125,000 | $4.00 | $500,000 | View SEC filing |
1-23 of 23
